Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Windtree TherapeuticsWINT +100.00% Days Inventory is 0.00 as of Sep. 2025. The stock has 2 warning signs investors should review. Among 638 Biotechnology companies, Windtree Therapeutics ranks worse than 156739.66% on this metric.
The historical rank and industry rank for Windtree Therapeutics's Days Inventory or its related term are showing as below:
During the past 13 years, Windtree Therapeutics's highest Days Inventory was 10.61. The lowest was 10.61. And the median was 10.61.
WINT's Days Inventory is not ranked *
in the Biotechnology industry.
Industry Median: 182.6 * Ranked among companies with meaningful Days Inventory only.
Windtree Therapeutics's Days Inventory
stayed the same
from Sep. 2024 (0.00) to Sep. 2025 (0.00).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Windtree Therapeutics (OTCPK:WINT) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Windtree Therapeutics's Inventory Turnover for the
three
months ended in Sep. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Windtree Therapeutics's Inventory to Revenue for the
three
months ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Windtree Therapeutics Days Inventory Related Terms
Windtree Therapeutics Days Inventory Historical Data
* Premium members only.
The historical data trend for Windtree Therapeutics's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WINT vs VRTX, REGN, RVMD: Days Inventory Comparison
For the Biotechnology subindustry, Windtree Therapeutics's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Windtree Therapeutics Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Windtree Therapeutics's Days Inventory distribution charts can be found below:
* The bar in red indicates where Windtree Therapeutics's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Windtree Therapeutics (WINT) has a Days Inventory of 0.00 as of Sep. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Windtree Therapeutics and its competitors. Over the past decade, Windtree Therapeutics' Days Inventory has ranged from 10.61 to 10.61. According to the industry distribution chart, Windtree Therapeutics ranks #999999 out of 638 companies in the Biotechnology industry.
Is Windtree Therapeutics' Days Inventory too high?
Windtree Therapeutics' current Days Inventory is 0.00. Over the past 10 years, this metric has ranged from a low of 10.61 to a high of 10.61. Based on the distribution chart, Windtree Therapeutics ranks #999999 out of 638 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Windtree Therapeutics' Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Windtree Therapeutics ranks #999999 out of 638 companies for Days Inventory. This places Windtree Therapeutics in the lower half of its industry. The industry median Days Inventory is 182.60. Historically, Windtree Therapeutics' own Days Inventory has ranged from 10.61 to 10.61 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 182.60, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Windtree Therapeutics and its competitors. For the Biotechnology industry, the median Days Inventory is 182.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Windtree Therapeutics's current Days Inventory is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windtree Therapeutics stock overvalued right now?
Windtree Therapeutics (WINT) has a current Days Inventory of 0.00. The current Days Inventory is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Windtree Therapeutics (WINT), the current Days Inventory is 0.00 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WINT has been successfully added to your 
